Methylphenidate Refill Screening for a 10-Year-Old
When refilling methylphenidate for a 10-year-old, you must systematically assess growth parameters (height and weight), cardiovascular status (blood pressure and heart rate), psychiatric symptoms, medication adherence, therapeutic efficacy, and adverse effects at every visit. 1
Essential Screening Questions and Assessments
Growth Monitoring (Critical Priority)
- Measure and plot height and weight at every refill visit 1
- Compare current measurements to previous growth trajectory
- CNS stimulants cause temporary growth suppression (average 2 cm less height, 2.7 kg less weight over 3 years) 1
- If growth is not progressing as expected, consider interrupting treatment 1
Cardiovascular Assessment
- Measure blood pressure and heart rate at every visit 1
- Expected increases: BP rises 2-4 mmHg, heart rate increases 3-6 bpm 1
- Ask about: chest pain, palpitations, syncope, exercise intolerance
- Screen for new cardiac symptoms that could indicate serious cardiac events 1
Psychiatric Symptom Monitoring
Ask parents and child about:
- New or worsening hallucinations, delusions, or manic symptoms (occurs in ~0.1% of patients) 1
- Changes in mood, increased anxiety, agitation, or aggressive behavior 1
- Suicidal thoughts or behaviors
- Screen for family history of bipolar disorder, depression, or suicide if not done previously 1
Tics and Movement Disorders
- Assess for new or worsening motor or verbal tics 1
- Ask about Tourette's syndrome symptoms
- Discontinue if tics become clinically significant 1
Medication-Specific Adverse Effects
Ask about:
- Sleep problems (very common) 1
- Appetite suppression (very common) 1
- Headaches, stomachaches, dizziness
- For male patients: any prolonged or painful erections (priapism can occur after dose increases or during withdrawal) 1
- Digital changes, color changes in fingers/toes, or Raynaud's phenomenon 1
Therapeutic Efficacy Assessment
- Ask parents AND teachers about ADHD symptom control in both settings 2
- Assess functioning at home and school
- Determine if current dose provides adequate symptom control throughout the day
- Confirm continued moderate-to-severe dysfunction warranting medication continuation 2
Medication Adherence and Misuse Risk
- Assess medication storage security (should be locked) 1
- Ask about missed doses, weekend/holiday dosing patterns
- Screen for signs of abuse, misuse, or diversion 1
- Ask if anyone else has requested or taken the medication
- Evaluate for dose escalation requests that seem inappropriate
Comorbidity Screening
- Assess for anxiety, depression, oppositional behavior
- Screen for academic difficulties or social problems
- Ask about any new behavioral concerns 2
Vision Assessment
- Ask about visual changes or eye pain (methylphenidate associated with increased intraocular pressure and angle-closure glaucoma) 1
Critical Safety Considerations
Contraindications to refilling:
- Known hypersensitivity reactions (angioedema, anaphylaxis) 1
- Current MAOI use or within 14 days of discontinuation 1
- New diagnosis of structural cardiac abnormalities or serious cardiac disease 1
Annual Re-evaluation Requirement
At least once yearly, formally reassess:
- Whether ADHD diagnosis remains accurate
- Whether medication is still necessary (consider trial off medication during school breaks)
- Whether current dose and formulation remain optimal
- Overall risk-benefit profile 2
Common Pitfalls to Avoid
- Do not refill without measuring height and weight - growth suppression is a significant concern requiring active monitoring 1
- Do not skip cardiovascular assessment - sudden cardiac death, though rare, has been reported 1
- Do not ignore new psychiatric symptoms - these may require immediate discontinuation 1
- Do not rely solely on parent report - teacher input is essential for comprehensive assessment 2
- Do not assume adherence - directly ask about medication storage, administration patterns, and potential diversion 1
The FDA labeling emphasizes that methylphenidate has high potential for abuse and misuse, requiring ongoing vigilance 1. The 2019 AAP guidelines stress that treatment should be multimodal and regularly reassessed 2. Growth monitoring is particularly critical in this age group (10 years old) as this falls within the period where growth suppression effects are most documented 1.